New anticonvulsant for Lennox-Gastaut syndrome

Eisai has launched Inovelon (rufinamide) for adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients from four years of age.

Lennox-Gastaut syndrome is a severe form of epilepsy, characterised by onset in early childhood of frequent seizures of multiple types.

Rufinamide is a broad-spectrum anticonvulsant that is structurally distinct from other antiepileptic drugs. It modulates the activity of neuronal sodium channels, prolonging their inactive state. Efficacy against seizures of Lennox-Gastaut syndrome has been demonstrated.

Further information: Eisai 020 8600 1400

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...